Treatment of exosome inhibitor GW4869 or suppression of S100A11 expression to diminish EIF3C-mediated HCC angiogenesis further suggested that up-regulated EIF3C expression in HCC is a theranostic target for HCC therapeutic interventions. Here, EIF3C is linked to hepatocellular carcinoma.